Zymeworks - ZYME Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $12.63
Forecasted Upside: 49.23%
Number of Analysts: 8
Breakdown:
0 Sell Ratings
3 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

^$8.46 As of 03/22/2023 04:46 PM ET

▼ -0.46 (-5.16%)

1 month | 3 months | 12 months

Get New Zymeworks Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ZYME and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZYME

^$12.63

▲ +49.23% Upside Potential

This price target is based on 8 analysts offering 12 month price targets for Zymeworks in the last 3 months. The average price target is $12.63, with a high forecast of $18.00 and a low forecast of $8.00. The average price target represents a 49.23% upside from the last price of $8.46.

Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in Zymeworks. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
4 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

9/28/2021

0 strong buy ratings
5 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/27/2021

0 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/27/2022

0 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

6/25/2022

0 strong buy ratings
6 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

9/23/2022

0 strong buy ratings
7 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/22/2022

0 strong buy ratings
6 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

2/20/2023

0 strong buy ratings
5 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/22/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/21/2023	Wells Fargo & Company	Reiterated Rating	Overweight	$12.00	Low
3/21/2023	HC Wainwright	Reiterated Rating	Neutral	$8.00	Low
3/10/2023	Citigroup	Lower Target		$21.00 ➝ $17.00	Low
3/8/2023	Guggenheim	Reiterated Rating	Buy	$16.00	Low
1/24/2023	HC Wainwright	Reiterated Rating	Neutral	$8.00	Low
1/20/2023	SVB Leerink	Boost Target	Market Perform	$8.00 ➝ $10.00	Low
1/19/2023	Guggenheim	Boost Target		$15.00 ➝ $16.00	Low
1/4/2023	HC Wainwright	Lower Target	Neutral	$10.00 ➝ $8.00	Low
12/22/2022	Barclays	Boost Target	Equal Weight	$7.00 ➝ $9.00	Low
12/19/2022	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$7.70 ➝ $11.00	Low
11/21/2022	HC Wainwright	Boost Target	Neutral	$8.00 ➝ $10.00	Low
11/1/2022	HC Wainwright	Downgrade	Buy ➝ Neutral	$40.00 ➝ $8.00	Low
10/24/2022	Stifel Nicolaus	Lower Target	Buy	$21.00 ➝ $18.00	Low
10/21/2022	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$19.00 ➝ $8.00	Low
10/4/2022	Wells Fargo & Company	Lower Target	Overweight	$45.00 ➝ $9.00	Low
9/14/2022	Citigroup	Lower Target		$27.00 ➝ $21.00	Low
8/29/2022	Citigroup	Lower Target	Buy	$28.00 ➝ $27.00	Low
5/27/2022	SVB Leerink	Boost Target	Outperform	$18.00 ➝ $19.00	Medium
5/23/2022	HC Wainwright	Lower Target	Buy	$44.00 ➝ $40.00	Medium
5/5/2022	Guggenheim	Upgrade	Neutral ➝ Buy	$14.00	Medium
3/15/2022	Evercore ISI	Initiated Coverage	Outperform	$15.00	High
2/28/2022	Citigroup	Lower Target		$53.00 ➝ $30.00	Low
2/9/2022	Wells Fargo & Company	Lower Target	Overweight	$56.00 ➝ $48.00	Medium
2/1/2022	Raymond James	Lower Target	Outperform	$50.00 ➝ $27.00	High
1/20/2022	Raymond James	Lower Target	Outperform	$74.00 ➝ $62.00	High
1/6/2022	Raymond James	Reiterated Rating	Outperform	$74.00	High
12/10/2021	SVB Leerink	Upgrade	Market Perform ➝ Outperform		Low
12/9/2021	Raymond James	Downgrade	Strong-Buy ➝ Outperform	$74.00	Low
11/15/2021	SVB Leerink	Reiterated Rating	Hold	$43.00	High
11/10/2021	SVB Leerink	Lower Target	Market Perform	$28.00 ➝ $27.00	High
11/4/2021	Raymond James	Set Target	Strong-Buy	$74.00	Low
11/4/2021	SVB Leerink	Lower Target	Market Perform	$43.00 ➝ $28.00	Medium
10/6/2021	Jefferies Financial Group	Initiated Coverage	Hold	$32.00	High
9/30/2021	Wells Fargo & Company	Reiterated Rating	Buy	$56.00	High
9/20/2021	HC Wainwright	Reiterated Rating	Buy	$44.00	Low
9/13/2021	Raymond James	Set Target	Strong-Buy	$74.00	Medium
8/6/2021	Raymond James	Reiterated Rating	Strong-Buy	$74.00	Medium
8/5/2021	HC Wainwright	Lower Target	Buy	$55.00 ➝ $44.00	High
5/7/2021	HC Wainwright	Lower Target	Buy	$57.00 ➝ $55.00	High
5/6/2021	Raymond James	Set Target	Strong-Buy	$74.00	Medium
3/30/2021	Credit Suisse Group	Initiated Coverage	Outperform	$55.00	High
3/3/2021	Raymond James	Set Target	Strong-Buy	$74.00	Medium
3/3/2021	SVB Leerink	Reiterated Rating	Outperform ➝ Market Perform	$50.00 ➝ $41.00	High
2/25/2021	Raymond James	Set Target	Strong-Buy	$74.00	High
2/25/2021	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$50.00 ➝ $41.00	High
2/8/2021	HC Wainwright	Reiterated Rating	Buy	$57.00	Low
2/3/2021	Raymond James	Set Target	Strong-Buy	$74.00	Low
1/29/2021	Citigroup	Upgrade	Neutral ➝ Buy		Low
1/28/2021	Wells Fargo & Company	Lower Target		$71.00 ➝ $56.00	Low
1/28/2021	Raymond James	Set Target	Strong-Buy	$74.00	Low
1/28/2021	SVB Leerink	Lower Target	Outperform	$66.00 ➝ $50.00	Low
1/28/2021	Barclays	Lower Target	Equal Weight	$47.00 ➝ $38.00	High
1/25/2021	Citigroup	Downgrade	Buy ➝ Neutral	$50.00 ➝ $53.00	High
1/19/2021	Raymond James	Boost Target	Strong-Buy	$60.00 ➝ $74.00	Medium
1/12/2021	Raymond James	Set Target	Strong-Buy	$60.00	High
1/12/2021	Wells Fargo & Company	Boost Target	Overweight	$58.00 ➝ $71.00	High
1/12/2021	SVB Leerink	Boost Target	Outperform	$45.00 ➝ $66.00	High
12/2/2020	Raymond James	Set Target	Strong-Buy	$60.00	Low
11/17/2020	Raymond James	Set Target	Strong-Buy	$60.00	High
11/4/2020	Raymond James	Set Target	Strong-Buy	$60.00	High
10/26/2020	Raymond James	Set Target	Strong-Buy	$60.00	Low
9/29/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral		Low
8/6/2020	Raymond James	Set Target	Strong-Buy	$60.00	Medium
8/6/2020	SVB Leerink	Initiated Coverage	Outperform	$45.00	Medium
7/16/2020	Raymond James	Set Target	Strong-Buy	$60.00	Low
7/14/2020	Guggenheim	Lower Target		$54.00 ➝ $48.00	Low
7/9/2020	Raymond James	Set Target	Strong-Buy	$60.00	Medium
7/9/2020	HC Wainwright	Lower Target	Buy	$60.00 ➝ $54.00	Medium
6/14/2020	Bloom Burton	Reiterated Rating	Buy		Low
6/3/2020	Raymond James	Set Target	Strong-Buy	$60.00	Low
6/2/2020	Citigroup	Boost Target	Buy	$49.00 ➝ $50.00	High
5/8/2020	Paradigm Capital	Reiterated Rating	Buy	$51.00	Medium
5/8/2020	Raymond James	Set Target	Strong-Buy	$60.00	High
5/8/2020	HC Wainwright	Reiterated Rating	Buy	$60.00	High
4/2/2020	Raymond James	Set Target	Strong-Buy	$60.00	Low
3/3/2020	HC Wainwright	Reiterated Rating	Buy	$65.00 ➝ $60.00	High
2/20/2020	HC Wainwright	Reiterated Rating	Buy	$65.00	Low
2/3/2020	Stifel Nicolaus	Boost Target	Buy	$45.00 ➝ $70.00	Medium
1/15/2020	Wells Fargo & Company	Reiterated Rating	Overweight	$48.00 ➝ $58.00	Low
1/14/2020	Raymond James	Reiterated Rating	Buy	$60.00	Low
1/10/2020	Wolfe Research	Initiated Coverage	Outperform	$61.00	High
12/9/2019	JPMorgan Chase & Co.	Initiated Coverage	Neutral	$43.00	High
11/27/2019	Guggenheim	Initiated Coverage	Buy	$48.00	Low
11/25/2019	Raymond James	Boost Target	Strong-Buy	$40.00 ➝ $60.00	Low
11/25/2019	HC Wainwright	Initiated Coverage	Buy	$65.00	High
11/21/2019	Stifel Nicolaus	Reiterated Rating	Buy		High
11/19/2019	Guggenheim	Initiated Coverage	Buy	$48.00	Medium
11/7/2019	Raymond James	Set Target	Strong-Buy	$40.00	High
10/29/2019	Raymond James	Set Target	Strong-Buy	$40.00	Low
10/17/2019	Raymond James	Reiterated Rating	Strong-Buy	$40.00	Low
9/30/2019	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$36.00 ➝ $40.00	High
9/27/2019	Raymond James	Set Target	Outperform	$36.00	High
8/30/2019	Stifel Nicolaus	Initiated Coverage	Buy	$45.00	High
8/27/2019	Citigroup	Boost Target	Buy	$22.00 ➝ $49.00	Medium
8/7/2019	Raymond James	Set Target	Outperform	$36.00	Low
8/5/2019	Barclays	Boost Target	Equal Weight	$15.00 ➝ $23.00	Medium
7/31/2019	Raymond James	Set Target	Outperform	$36.00	Medium
7/18/2019	Raymond James	Reiterated Rating	Outperform	$36.00	Low
7/18/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy ➝ Buy	$34.00	Medium
5/30/2019	Raymond James	Reiterated Rating	Outperform	$36.00	High
5/15/2019	Raymond James	Set Target	Outperform	$36.00	Low
5/3/2019	Raymond James	Set Target	Outperform	$36.00	Low
4/26/2019	Raymond James	Boost Target	Outperform	$29.00 ➝ $36.00	Low
4/22/2019	Wells Fargo & Company	Boost Target	Outperform	$37.00 ➝ $42.00	Low
3/14/2019	Raymond James	Set Target	Outperform	$29.00	Medium
3/8/2019	Raymond James	Reiterated Rating	Outperform	$29.00	Low
12/10/2018	Raymond James	Set Target	Outperform	$29.00	Medium
11/28/2018	Raymond James	Boost Target	Outperform	$27.00 ➝ $29.00	High
10/15/2018	Raymond James	Set Target	Outperform	$27.00	Low
9/5/2018	Raymond James	Set Target	Buy	$27.00	Low
8/15/2018	Raymond James	Reiterated Rating	Buy	$27.00	Low
8/2/2018	Citigroup	Upgrade	Neutral ➝ Buy	$19.00	High
6/21/2018	Citigroup	Lower Target	Neutral ➝ Neutral	$20.00 ➝ $19.00	Low
6/6/2018	Citigroup	Downgrade	Buy ➝ Neutral		High
6/5/2018	Raymond James	Boost Target	Outperform ➝ Outperform	$22.00 ➝ $27.00	Medium
6/4/2018	Wells Fargo & Company	Boost Target	Outperform ➝ Outperform	$20.00 ➝ $37.00	Medium
5/18/2018	Raymond James	Boost Target	Outperform	$18.00 ➝ $22.00	Low
5/14/2018	LADENBURG THALM/SH SH	Initiated Coverage	Buy	$25.00	Low
5/11/2018	Barclays	Upgrade	Underweight ➝ Equal Weight	$8.00 ➝ $15.00	High

(Data available from 3/22/2018 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

2 very positive mentions
8 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

8/24/2022

2 very positive mentions
11 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

9/23/2022

5 very positive mentions
19 positive mentions
2 negative mentions
2 very negative mentions

Mentions as of

10/23/2022

2 very positive mentions
4 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

11/22/2022

0 very positive mentions
4 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

12/22/2022

5 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/21/2023

4 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/20/2023

3 very positive mentions
7 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/22/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

marketbeat.com
3/21/2023
Zymeworks (NYSE:ZYME) Receives "Overweight" Rating from Wells Fargo & Company
americanbankingnews.com
3/14/2023
SVB Leerink Comments on Zymeworks Inc.'s Q1 2023 Earnings (NYSE:ZYME)
marketbeat.com
3/10/2023
Citigroup Trims Zymeworks (NYSE:ZYME) Target Price to $17.00
marketbeat.com
3/9/2023
Zymeworks Offers Hope for More than Just Long-Term Investors
marketbeat.com
2/28/2023
Zymeworks (ZYME) Set to Announce Quarterly Earnings on Tuesday

Very Positive

marketbeat.com
3/12/2023
Research Analysts Issue Forecasts for Zymeworks Inc.'s Q1 2023 Earnings (NYSE:ZYME)
marketbeat.com
3/3/2023
Zymeworks Inc. (NYSE:ZYME) Position Trimmed by CI Investments Inc.
marketbeat.com
2/24/2023
Armistice Capital LLC Has $35.58 Million Holdings in Zymeworks Inc. (NYSE:ZYME)

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Today's Range

Now: $8.46

$8.37

$8.92

50 Day Range

MA: $8.92

$7.93

$10.04

52 Week Range

Now: $8.46

$4.11

$10.80

Volume

352,679 shs

Average Volume

710,473 shs

Market Capitalization

$541.78 million

P/E Ratio

4.78

Dividend Yield

N/A

Beta

0.91

Frequently Asked Questions

What sell-side analysts currently cover shares of Zymeworks?: The following Wall Street research analysts have issued reports on Zymeworks in the last year: Barclays PLC, Citigroup Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Stifel Nicolaus, SVB Leerink LLC, and Wells Fargo & Company.
View the latest analyst ratings for ZYME.
What is the current price target for Zymeworks?: 8 Wall Street analysts have set twelve-month price targets for Zymeworks in the last year. Their average twelve-month price target is $12.63, suggesting a possible upside of 49.2%. Stifel Nicolaus has the highest price target set, predicting ZYME will reach $18.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for Zymeworks in the next year.
View the latest price targets for ZYME.
What is the current consensus analyst rating for Zymeworks?: Zymeworks currently has 3 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZYME will outperform the market and that investors should add to their positions of Zymeworks.
View the latest ratings for ZYME.
What other companies compete with Zymeworks?: Other companies that are similar to Zymeworks include BioXcel Therapeutics, Cogent Biosciences, Lyell Immunopharma, Janux Therapeutics and Altimmune. Learn More about companies similar to Zymeworks.
How do I contact Zymeworks' investor relations team?: Zymeworks' physical mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company's listed phone number is (302) 274-8744 and its investor relations email address is [email protected] The official website for Zymeworks is www.zymeworks.com. Learn More about contacing Zymeworks investor relations.

Zymeworks - ZYME Stock Price Target and Predictions

Analyst Price Target for ZYME

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.71 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Zymeworks?

What is the current price target for Zymeworks?

What is the current consensus analyst rating for Zymeworks?

What other companies compete with Zymeworks?

How do I contact Zymeworks' investor relations team?